Upregulation of Periostin and Reactive Stroma Is Associated with Primary Chemoresistance and Predicts Clinical Outcomes in Epithelial Ovarian Cancer
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Purpose: Up to one third of ovarian cancer patients are intrinsically resistant to platinum-based treatment. However, predictive and therapeutic strategies are lacking due to a poor understanding of the underlying molecular mechanisms. This study aimed to identify key molecular characteristics that are associated with primary chemoresistance in epithelial ovarian cancers. Experimental Design: Gene expression profiling was performed on a discovery set of 85 ovarian tumors with clinically well-defined response to chemotherapies as well as on an independent validation dataset containing 138 ovarian patients from the chemotreatment arm of the ICON7 trial. Results: We identified a distinct “reactive stroma” gene signature that is specifically associated with primary chemoresistant tumors and was further upregulated in posttreatment recurrent tumors. Immunohistochemistry (IHC) and RNA in situ hybridization (RNA ISH) analyses on three of the highest-ranked signature genes (POSTN, LOX, and FAP) confirmed that modulation of the reactive stroma signature genes within the peritumoral stromal compartments was specifically associated with the clinical chemoresistance. Consistent with these findings, chemosensitive ovarian cells grown in the presence of recombinant POSTN promoted resistance to carboplatin and paclitaxel treatment in vitro. Finally, we validated the reactive stroma signature in an independent dataset and demonstrated that a high POSTN expression level predicts shorter progression-free survival following first-line chemotherapy. Conclusions: Our findings highlight the important interplay between cancer and the tumor microenvironment in ovarian cancer biology and treatment. The identified reactive stromal components in this study provide a molecular basis to the further development of novel diagnostic and therapeutic strategies for overcoming chemoresistance in ovarian cancer. Clin Cancer Res; 21(13); 2941–51. ©2015 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kalluri, R., & Zeisberg, M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1877 · Cited by 4,538 · cited 1×
“Reactive stroma in cancer has similarities to the biology of the wound-healing process in normal tissues, where stromal cells exhibit elevated production of extracellular matrix (ECM) components, growth factors, and matrix-remodeling enzymes to create a tumor microenvironment that promotes cancer cell survival, prolif…”
Background(2012) · doi:10.1016/j.jmoldx.2011.08.002 · Cited by 2,567 · cited 1×
“2, nt 13–1199) RNA using custom software as described previously (11).”
MethodHigh Interstitial Fluid Pressure - an Obstacle in Cancer Therapy
Heldin, C.-H., Rubin, K., Pietras, K., & Östman, A. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1456 · Cited by 2,222 · cited 1×
“These changes have been suggested to contribute to chemoresistance in cancer (20, 21).”
BackgroundDirect multiplexed measurement of gene expression with color-coded probe pairs
Geiss, G. K., Bumgarner, R. E., Birditt, B., Dahl, T., Dowidar, N., Dunaway, D. L., Fell, H. P., Ferree, S., George, R. D., Grogan, T., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1385 · Cited by 2,066 · cited 9×
“org Clin Cancer Res; 21(13) July 1, 2015 2945”
BackgroundMethodInfluentialFormation and function of the myofibroblast during tissue repair
Hinz, B. (2007) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700613 · Cited by 1,658 · cited 1×
“The POSTN/LOX/FAP expressing tumorassociated fibroblasts also showed strong alpha-smooth muscle actin (αSMA) staining, which is an established marker of an activated myofibroblasts phenotype (18).”
BackgroundInteractions between cancer stem cells and their niche govern metastatic colonization
Malanchi, I., Santamaria-Martínez, A., Susanto, E., Peng, H., Lehr, H.-A., Delaloye, J.-F., & Huelsken, J. (2012) · Nature · doi:10.1038/nature10694 · Cited by 1,339
Stromal cells in tumor microenvironment and breast cancer
Mao, Y., Keller, E. T., Garfield, D. H., Shen, K., & Wang, J. (2013) · Cancer and Metastasis Reviews · doi:10.1007/s10555-012-9415-3 · Cited by 671 · cited 1×
“Activation of the host stromal microenvironment, commonly referred as to “reactive stroma”, has been implicated as a critical component of carcinoma progression in many types of cancers (3-6).”
BackgroundGene Expression Profiles Associated with Response to Chemotherapy in Epithelial Ovarian Cancers
Jazaeri, A. A., Awtrey, C. S., Chandramouli, G. V. R., Chuang, Y. E., Khan, J., Sotiriou, C., Aprelikova, O., Yee, C. J., Zorn, K. K., Birrer, M. J., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2682 · Cited by 192
Cited by
Hegde, P. S., Karanikas, V., & Evers, S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1507 · Cited by 1,000
Hornburg, M., Desbois, M., Lu, S., Guan, Y., Lo, A. A., Kaufman, S., Elrod, A., Lotstein, A., DesRochers, T. M., Munoz-Rodriguez, J. L., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.04.004 · Cited by 383
Self-citationPeriostin: A Matricellular Protein With Multiple Functions in Cancer Development and Progression
González-González, L., & Alonso, J. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00225 · Cited by 284
Collagen Remodeling in the Hypoxic Tumor-Mesothelial Niche Promotes Ovarian Cancer Metastasis
Natarajan, S., Foreman, K. M., Soriano, M. I., Rossen, N. S., Shehade, H., Fregoso, D. R., Eggold, J. T., Krishnan, V., Dorigo, O., Krieg, A. J., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2616 · Cited by 129
“Recent studies have shown that LOX expression is associated with ovarian cancer metastasis, chemoresistance, and poor survival (35, 46, 47).”
BackgroundDeterminants and functions of CAFs secretome during cancer progression and therapy
Linares, J., Marín-Jiménez, J. A., Badia-Ramentol, J., & Calon, A. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.621070 · Cited by 110
“In lung cancer, the soluble fraction of VCAM-1 predicted relapse and lower OS, whereas high POSTN expression was associated with shorter PFS in ovarian cancer patients (Ryner et al., 2015; Zhou et al., 2020).”
Background
Metadata
- Authors
- Ryner, L., Guan, Y., Firestein, R., Xiao, Y., Choi, Y., Rabe, C., Lu, S., Fuentes, E., Huw, L.-Y., Lackner, M. R., Fu, L., Amler, L. C., Bais, C., & Wang, Y.
- Venue
- Clinical Cancer Research
- Published
- 2015-06-30
- Volume
- 21
- Issue
- 13
- Pages
- 2941-2951
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2122920182
- Cited by
- 107
- References
- 8
- FWCI
- 9.17
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Upregulation of Periostin and Reactive Stroma Is Associated with Primary Chemoresistance and Predicts Clinical Outcomes in Epithelial Ovarian Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-14-3111
- The paper
- Ryner, L., Guan, Y., Firestein, R., Xiao, Y., Choi, Y., Rabe, C., Lu, S., Fuentes, E., Huw, L.-Y., Lackner, M. R., Fu, L., Amler, L. C., Bais, C., & Wang, Y. (2015). Upregulation of Periostin and Reactive Stroma Is Associated with Primary Chemoresistance and Predicts Clinical Outcomes in Epithelial Ovarian Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-14-3111
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.